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ABSTRACT
Objective To evaluate the effect of vitamin E
supplementation on incident total, ischaemic, and
haemorrhagic stroke.
Design Systematic review and meta-analysis of
randomised, placebo controlled trials published until
January 2010.
Data sources Electronic databases (Medline, Embase,
Cochrane Central Register of Controlled Trials) and
reference lists of trial reports.
Selection criteria Randomised, placebo controlled trials
with ≥1 year of follow-up investigating the effect of
vitamin E on stroke.
Review methods and data extraction Two investigators
independently assessed eligibility of identified trials.
Disagreementswereresolvedbyconsensus.Twodifferent
investigators independently extracted data. Risk ratios
(and 95% confidence intervals) were calculated for each
trial based on the number of cases and non-cases
randomised to vitamin E or placebo. Pooled effect
estimates were then calculated.
Results Nine trials investigating the effect of vitamin E on
incident stroke were included, totalling 118765
participants (59357 randomised to vitamin E and 59408
to placebo). Among those, seven trials reported data for
total stroke and five trials each for haemorrhagic and
ischaemic stroke. Vitamin E had no effect on the risk for
total stroke (pooled relative risk 0.98 (95% confidence
interval 0.91 to 1.05), P=0.53). In contrast, the risk for
haemorrhagic stroke was increased (pooled relative risk
1.22 (1.00 to 1.48), P=0.045), while the risk of ischaemic
stroke was reduced (pooled relative risk 0.90 (0.82 to
0.99),P=0.02).Therewaslittleevidenceforheterogeneity
among studies. Meta-regression did not identify blinding
strategy, vitamin E dose, or morbidity status of
participants as sources of heterogeneity. In terms of
absolute risk, this translates into one additional
haemorrhagic stroke for every 1250 individuals taking
vitamin E, in contrast to one ischaemic stroke prevented
per 476 individuals taking vitamin E.
Conclusion In this meta-analysis, vitamin E increased the
risk for haemorrhagic stroke by 22% and reduced the risk
of ischaemic stroke by 10%. This differential risk pattern
is obscured when looking at total stroke. Given the
relativelysmallriskreductionofischaemicstrokeandthe
generally more severe outcome of haemorrhagic stroke,
indiscriminate widespread use of vitamin E should be
cautioned against.
INTRODUCTION
VitaminEisalipidsolubleantioxidantbestknownfor
its ability to inhibit lipid peroxidation by scavenging
reactive oxygen species and to preserve cell
membranes.
1Cardiovascular diseaseislargelyattribu-
table to atherogenesis, and lipid peroxidation plays a
central role in atherogenesis.
2 This has raised hopes
that antioxidants including vitamin E may protect
against cardiovascular disease. Data from observa-
tionalstudiessupportthisview,suggestingaprotective
effectagainstcoronaryheartdisease.
3-5Asaresult,sup-
plementation with vitamins has become popular, and
more than half of the adult population in the United
States is taking dietary supplements; including 12.7%
taking vitamin E.
6
A number of large, randomised, placebo controlled
trials
7-14 and two meta-analyses
1516 investigated the
effectsofvitaminEonincidentcardiovasculardisease.
The results were largely disappointing, and no overall
effect of vitamin E on main composite end points,
including myocardial infarction, total stroke, or death
duetocardiovasculardisease,werefound.Inaddition,
concerns have been raised that high dose vitamin E
may increase the risk for all cause mortality.
17
Although randomised controlled trials are consid-
ered the ideal for investigating the effects of inter-
ventions on disease, the biological diversity of
cardiovascular disease has not been adequately
acknowledgedintheavailabletrials.Thereisevidence
that the underlying pathophysiology is different for
myocardial infarction and stroke. In addition, stroke
does not represent a single well defined entity; the
mechanisms underlying ischaemic and haemorrhagic
events are different.
1819 Thus, choosing composite
main outcomes may dilute effects on individual out-
comes. There is evidence for differential effects from
theavailabletrials.Whileresultsfrommosttrialsagree
that vitamin E has no overall effect on myocardial
infarction,
9111314 the evidence for stroke, including
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tion that vitamin E may be beneficial for incident
ischaemic stroke
912 but detrimental for incident hae-
morrhagic stroke.
913
As stroke remains a leading cause of death and
disability
20 and vitamin E supplements are widely
used and readily available, clarification of potential
opposing associations of vitamin E with ischaemic
andhaemorrhagicstrokeisofsubstantialpublichealth
importance. We therefore systematically searched the
literature for randomised, placebo controlled trials of
vitamin E that reported on incident stroke and stroke
subtypes and performed a meta-analysis.
METHODS
Data sources and searches
We followed the guidelines for reports of meta-
analyses of randomised controlled trials according to
the PRISMA statement.
21 Two investigators (MS and
TK) independently searched Medline and Embase
(from inception to January 2010) as well as the
CochraneCentralRegisterofControlledTrials(CEN-
TRAL) (issue 1, 2010), combining text terms and,
where appropriate, MeSH terms for vitamin E
(“vitamin E” or “alpha tocopherol”) and stroke
(“cerebrovascular disorders” or “cerebrovascular dis-
ease” or “stroke” or “intracranial hemorrhage” or
“brain hemorrhage”). The search terms were com-
bined with the “explode” feature. We limited our
search to humans, clinical trials, randomised con-
trolled trials, meta-analyses, and systematic reviews.
We did not apply language restrictions. We also
searched the reference lists of the identified articles.
Study selection
A priori, we defined the following inclusion criteria:
(1) Randomised, placebo controlled design with a
follow-up of ≥1 year
(2) Investigating the effect of vitamin E on stroke
incidence (total stroke or stroke subtypes)
(3) Trial participants must be selected on clinical
grounds
(4) If multiple papers reported on a trial, we chose
either the original report or the report that was most
informative with regard to stroke and stroke
subtypes.
Wedidnotincludetrialsofmultivitaminsorfixedvita-
min combinations.
Two investigators (MS and TK) screened the titles
and abstracts and identified and excluded all papers
not meeting any of the prespecified criteria by consen-
sus. The same investigators evaluated the remaining
studies as full papers. Studies were excluded if they
did not meet all criteria.
Data extraction
Two investigators (MS and PMR) independently
extracted data and entered them in a customised data-
base. Disagreements were resolved by consensus.
Extracted data included authors and title of study,
year of publication, country of origin, blinding strat-
egy, participant age at enrolment and sex, inclusion
criteria, treatment dose, method of statistical analysis,
duration and completeness of follow-up, number of
participants, and number of outcome events in each
of the treatment groups. All data were extracted from
thepublishedpapers;wedidnotcontacttheauthorsto
collect further information.
Data synthesis and analysis
Within each study, we calculated the risk ratio as a
measurefortherelativeriskand95%confidenceinter-
val for total stroke, ischaemic stroke, and haemorrha-
gicstrokebasedonthereportedeventsinthetreatment
and placebo groups.
We used a fixed effects model (Mantel-Haenszel
method) and random effects model (DerSimonian
and Laird method) to investigate the effect of vitamin
Eonstrokeacrossthetrialsandcalculatedpooledrela-
tive risks and 95% confidence intervals.
22 We per-
formed the Q test for heterogeneity
23 and also
calculated the I
2 statistic.
24 We used meta-regression
to evaluate to which extent heterogeneity between
study results is related to blinding strategy (open label
v double blind), morbidity status of participants (pri-
mary v secondary prevention), and vitamin E dose
(≤200 mg/day v >200 mg/day; <200 mg/day v
≥200 mg/day; 50 mg/day v >50 mg/day). We used
Galbraith plots to visually examine the impact of indi-
vidual studies on the overall homogeneity test
statistic.
25 We formally tested for small study effects
(such as publication bias) by using Harbord’s test.
26
We considered a two tailed P value <0.05 as signifi-
cant. All analyses were performed with Stata 10.1
(Stata, College Station, Texas, USA). Since we used
only previously published data, we did not need
approval of an ethics committee.
RESULTS
Fig 1 summarises the process of identifying eligible
randomised controlled trials. After title and abstract
evaluation, we were left with 22 articles. We excluded
14morearticlesnotmeetingourinclusioncriteriaafter
evaluating the full text articles: eight articles presented
subgroup or additional analyses of trials already
included; one article was a meta-analysis; one article
reported a follow-up of less than a year; one study did
not have a placebo control group; two trials used toco-
pheryl nicotinate, not α-tocopherol (vitamin E); and
one study was not a randomised controlled trial. We
identified one additional article
7 by manually search-
ing reference lists of included articles and reviews.
Thus, nine trials were included in this analysis.
7-1427
Study characteristics
The characteristics of the included randomised con-
trolled trials are summarised in the table. The total
number of participants in the trials was 118765
(59357 randomised to vitamin E and 59408 to pla-
cebo). One study did not specify the method of
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27 all other trials were analysed according to
the intention to treat principle.
TheCambridgeHeartAntioxidantStudy(CHAOS)
was a double blind, randomised controlled trial inves-
tigating the effect of vitamin E among 2002 patients
with angiographically proved atherosclerosis.
7 Vita-
min E significantly reduced the incidence of the pri-
mary end points non-fatal myocardial infarction
(relative risk 0.23 (95% confidence interval 0.11 to
0.47)) and the composite of non-fatal myocardial
infarction and cardiovascular death (relative risk 0.53
(0.34 to 0.83)).
TheGruppoItalianoperloStudiodellSopravivenza
nell’Infarto miocardico (GISSI) Prevenzione trial was
an open label, randomised controlled trial using a 2×2
factorial design to investigate the treatment of vitamin
E and n-3 polyunsaturated fatty acids among 11324
patients with recent myocardial infarction.
10 Patients
randomised to vitamin E had no reduced risk for the
primary composite end point of death, non-fatal myo-
cardial infarction, and stroke (two way analysis: odds
ratio 0.95 (0.86 to 1.05)).
The Secondary Prevention with Antioxidants of
Cardiovascular Disease in Endstage Renal Disease
(SPACE) trial was a double blind, randomised con-
trolled trial of vitamin E among 196 patients receiving
haemodialysis with a history of cardiovascular
events.
27 Vitamin E reduced the risk for the primary
composite end point of myocardial infarction, ischae-
mic stroke, peripheral vascular disease, and unstable
angina (relative risk 0.46 (0.27 to 0.78)).
The Heart Outcomes Prevention Evaluation
(HOPE) trial was a double blind, randomised con-
trolled trial using a 2×2 factorial design to test the
effects of ramipril and vitamin E among 9541 patients
with high risk for cardiovascular disease.
14 Vitamin E
hadnoapparenteffectonthemaincompositeoutcome
of myocardial infarction, stroke, and death from
cardiovascular disease (relative risk 1.05 (0.95 to
1.16)).
The Alpha Tocopherol, Beta Carotene Cancer Pre-
vention(ATBC)studywasadoubleblind,randomised
controlled trial to test α-tocopherol and β carotene
among male smokers with no other previous serious
illnesses. The analysis among 28519 men free of
cardiovascular disease suggested no overall effects of
vitaminEonstrokes.
12However,theriskforischaemic
stroke was reduced (relative risk 0.86 (0.75 to 0.99)),
whereas the risk for subarachnoid haemorrhages
seemed elevated (relative risk 1.50 (0.97 to 2.32)).
The Primary Prevention Project (PPP) was an open
label, randomised controlled trial among 4495 partici-
pants with cardiovascular risk factor but without overt
cardiovascular disease, investigating the effect of
aspirinandvitaminEwitha2×2factorialdesign.
8Vita-
minEdidnotaltertheriskforthemaincompositeend
point of cardiovascular death, non-fatal myocardial
infarction, and non-fatal stroke (relative risk 1.07
(0.74 to 1.56)).
The Women’s Health Study (WHS) was a double
blind, randomised controlled trial with a 2×2 factorial
design to test the effects of aspirin and vitamin E on
cardiovascular disease and cancer among 39876
apparently healthy women.
11 Vitamin E did not show
a benefit on the main composite outcome of non-fatal
myocardial infarction, non-fatal stroke, and cardio-
vascular death (relative risk 0.93 (0.82 to 1.05)).
The Women’s Antioxidant Cardiovascular Study
(WACS) was a double blind randomised controlled
trial testing the effects of vitamin C, vitamin E, and β
carotenein8171womenathighriskforcardiovascular
disease with a 2×2×2 factorial design.
9 Treatment with
vitamin E did not change the risk for the composite
primary end point of myocardial infarction, stroke,
coronary revascularisation procedures, and cardio-
vascular death (relative risk 0.94 (0.85 to 1.04)).
The Physicians’ Health Study II (PHS II) was a dou-
bleblindrandomisedcontrolledtrialwitha2×2factor-
ialdesigninvestigatingtheeffectsofvitaminE,vitamin
C, a multivitamin, and β carotene on cardiovascular
disease and cancer among 14641 men.
13 Vitamin E
didnotchangetheriskforthemainoutcomeconsisting
of non-fatal myocardial infarction, non-fatal stroke,
and cardiovascular death (relative risk 0.90 (0.90 to
1.13)). However, the risk for haemorrhagic stroke was
elevated (relative risk 1.74 (1.04 to 2.91)).
Effect of vitamin E on stroke
Seven clinical trials provided information about total
stroke(fig2).
8-14Noneoftheresultsfromtheindividual
trials suggested that vitamin E significantly alters the
risk for total stroke. A total of 1438 strokes occurred
among the 58225 participants randomised to vitamin
E, and 1475 strokes occurred among the 58342 parti-
cipants randomised to placebo (fixed effects model,
Articles included (n=9)
CENTRAL
Articles found
(n=156)
Embase
Articles found
(n=157)
Medline
Articles found
(n=108)
Additional article included after manually
searching reference lists (n=1)
Articles after duplicates removed (n=272)
Articles excluded (n=250):
  Irrelevant outcomes or topics (n=188)
  Reviews (n=28)
  Editorials, comments, case reports (n=29)
  Only vitamin combinations investigated (n=5)
Full articles obtained (n=22)
Articles excluded (n=14):
  Subgroup or additional analyses of trials already
    included (n=8)
  Meta-analysis (n=1)
  Follow-up of <1 year (n=1)
  No placebo control group (n=1)
  Used tocopheryl nicotinate, not α-tocopherol (n=2)
  Not a randomised controlled trial (n=1)
Fig 1 | Flow chart of identifying and including trials
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wasno evidence for heterogeneity betweenthe studies
(I
2=12.8%; P for heterogeneity=0.33), and results were
similar when we used a random effects model (pooled
relative risk 0.98 (0.90 to 1.06), P=0.61). Accordingly,
meta-regression did not suggest that blinding strategy
(P=0.75), morbidity status of participants (P=0.96), or
vitamin E dose(allP>0.2) were sourcesof heterogene-
ity. Formal investigation with Harbord’s test gave no
evidence for a small study effect (P=0.63). The results
weresimilarforfatalandnon-fataltotalstroke(datanot
shown).
The effect of vitamin E analysed by type of stroke
showed contrasting results. Results from five trials
reported haemorrhagic stroke outcomes (fig 3).
911-14
All trials were double blinded. Although results of
four trials suggested increases in the relative risks of
haemorrhagic stroke among participants receiving
vitaminE,onlytheresultsfromthePhysicians’Health
StudyIIreachedstatisticalsignificance.
13Inthepooled
analysis, a total of 223 haemorrhagic strokes occurred
among 50334 individuals assigned to vitamin E and
183 haemorrhagic strokes occurred among the
50414 individuals assigned to placebo (fixed effects
model, pooled relative risk 1.22 (1.00 to 1.48),
P=0.045). There was no evidence for heterogeneity
among trials (I
2=0.0%; P for heterogeneity=0.44), and
results were the same when using a random effects
model (pooled relative risk 1.22 (1.00 to 1.48),
P=0.048). Meta-regression did not suggest that mor-
bidity status of participants (P=0.65) or vitamin E
dose(allP>0.4)weresourcesofheterogeneity. Formal
investigation with Harbord’s test gave no evidence for
a small study effect (P=0.56).
Reports from five trials allowed calculating effect
estimates for ischaemic stroke (fig 4).
911-1327 Results
for three of the five individual trials indicated slightly
reducedrelativerisksofischaemicstrokeamongthose
assigned to vitamin E, but none of the results reached
statistical significance. In the pooled analysis, a total of
884 ischaemicstrokes occurred among the 45670 par-
ticipants randomised to vitamin E and 983 among the
45733randomisedtoplacebo,translatingintoasignif-
icant 10% risk reduction (fixed effects model, pooled
relative risk 0.90 (0.82 to 0.99), P=0.02). There was no
evidenceforheterogeneity(I
2=0.0%;Pforheterogene-
ity=0.62), and results did not change with a random
effects model (pooled relative risk 0.90 (0.82 to 0.99),
P=0.02). Meta-regression did not suggest that morbid-
itystatusof participants(P=0.40)or vitaminEdose(all
P>0.4) were a source of heterogeneity. Formal investi-
gationwithHarbord’stestgavenoevidenceforasmall
study effect (P=0.97).
Absolute risks
Among participants randomly assigned to vitamin E,
the incidence rates per 1000 were 24.7 for total stroke,
4.4 for haemorrhagic stroke, and 19.4 for ischaemic
Characteristics of the nine randomised controlled trials of vitamin E on stroke outcomes
Trial Study design
Participant details
Type of
prevention
Vitamin E
dose (source)
Follow-up details
Available data
for stroke
outcomes
Total
No
Age at
enrolment
(years) Sex Health status
Duration
(years) Completeness
CHAOS 1996 (GB)
7 DoubleblindRCT 2 002 Mean: 61.8 Mixed Patients with
angiographically proved
coronary atherosclerosis
Secondary 400 or 800 IU
daily (natural)
Median
1.4*
98% Total (only fatal)
GISSI 1999 (Italy)
10 Open label RCT 11 324 No limit Mixed MI within 3 months Secondary 300 mg daily
(synthetic)
3.4† 99.9% Total
SPACE 2000
(Israel)
20
DoubleblindRCT 196 40–75 Mixed Haemodialysispatientswith
history of CVD events
Secondary 800 IU daily
(natural)
Median
1.4*
Not stated Ischaemic
HOPE 2000
(international)
14
DoubleblindRCT 9 541 ≥55 Mixed High risk for CVD including
previous CVD events,
vascular disease, or
diabetes
Secondary 400 IU daily
(natural)
Mean 4.5 99.9% (mortality) Total,
haemorrhagic
ATBC 2000
(Finland)
12
DoubleblindRCT 28 519 50–69 Men Smokers, no cancer, no
other serious illnesses, no
previous stroke
Primary 50 mg daily
(synthetic)
Median
6.0
100% Total, fatal,
ischaemic,
haemorrhagic
PPP 2001 (Italy)
8 Open label RCT 4 495 ≥50 Mixed ≥1 CVD risk factor, no overt
CVD event
Primary 300 mg daily
(synthetic)
Mean 3.6,
median
4.0
92.3% (overall);
99.3% (mortality)
Total, fatal, non-
fatal
WHS 2005 (US)
11 DoubleblindRCT 39 876 ≥45 Women NohistoryofCVD,cancer,or
other major disease
Primary 600 IU every
other day
(natural)
Mean 10.1 97.2%
(morbidity);
99.4% (mortality)
Total, fatal, non-
fatal, ischaemic,
haemorrhagic
WACS 2007 (US)
9 DoubleblindRCT 8 171 ≥40 Women High risk for CVD: history of
CVD event or ≥3 cardiac risk
factors
Secondary 600 IU every
other day
(natural)
Mean 9.4 93% (morbidity);
93% (mortality)
Total, fatal, non-
fatal, ischaemic,
haemorrhagic
PHS II 2008 (US)
13 DoubleblindRCT 14 641 ≥50 Men Mostly healthy; 5.1% had
prevalent CVD
Primary 400 IU every
other day
(synthetic)
Mean 8.0,
median
7.6
99.9%
(morbidity);
99.9% (mortality)
Total, fatal, non-
fatal, ischaemic,
haemorrhagic
RCT=randomised controlled trial; CVD=cardiovascular disease.
*Calculated as (No of days of follow-up)/365.25.
†Calculated as (person years)/(No of participants).
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incidence rates per 1000 were 25.3, 3.6, and 21.5
respectively. This translates into a risk difference per
1000treatedpeopleof0.6fewertotalstrokes,0.8more
haemorrhagicstrokes,and2.1fewerischaemicstrokes.
In other words, for every 1250 individuals taking vita-
min E, one haemorrhagic stroke occurs; whereas one
ischaemicstrokeispreventedforevery476individuals
treated.
Sensitivity analyses
ByvisuallyexaminingGalbraithplots,wedidnotiden-
tify trial results that fell outside the margins set by two
standard deviations from the mean for all evaluated
outcomes. For the analysis on ischaemic stroke, we
excluded the trial that did not specify if the analysis
was performed according to the intention to treat
method.
27 This did not change the results (fixed effects
model, relative risk 0.90 (0.82 to 0.99), P=0.02).
DISCUSSION
This meta-analysis of randomised controlled trials of
vitamin E treatment reporting on stroke outcomes
indicatesthat the risk of haemorrhagic strokeis signifi-
cantly increased by 22% whereas the risk of ischaemic
stroke is significantly reduced by 10%. These associa-
tionsareobscuredwhentotalstrokeisevaluatedasthe
outcome.
Strengths and limitations of study
Strengths of our study include the thorough rando-
mised, placebo controlled design of the individual
included trials, the large number of trial participants
for whom data on ischaemic and haemorrhagic stroke
were available, and our adherence to the standardised
guidelines on the reporting of systematic reviews
according to the PRISMA statement.
21
The following limitations of our meta-analysis
should be considered. First, we decided a priori to
include only trials that investigated the effect of
“pure” vitamin E supplements on stroke and excluded
those using fixed antioxidant vitamin combinations or
multivitamins.
28 Trials of combinations preclude con-
clusions regarding the sole effect of vitamin E, since
interactionsbetweensinglecomponentscannotbepre-
dicted.
Second, we considered randomised controlled trials
irrespectiveofblindingandmorbiditystatusofpartici-
pants. This approach increases the total sample size
and thus the power to detect a potential effect of vita-
min E on stroke subtypes and also allows for greater
flexibilityattheanalysislevelbyperformingsensitivity
analyses. Methodological quality is an important con-
sideration when combining trials in a meta-analysis.
29
Forexample,largereffectshavebeenreportedintrials
thatwerenotdoubleblindedcomparedwiththosethat
weredoubleblinded.
30Althoughqualityscalesforclin-
ical trials are available, they are not generally recom-
mendedtoassessqualityinsystematicreviews.
29Meta-
regression may be a better tool to investigate if metho-
dological differences are a source of heterogeneity
  GISSI 199910
  HOPE 200014
  ATBC 2000
12
  PPP 20018
  WHS 200511
  WACS 20079
  PHS II 200813
Pooled results
  Fixed effects model
  Random effects model
0.87 (0.65 to 1.17)
1.17 (0.96 to 1.42)
0.93 (0.83 to 1.05)
1.24 (0.67 to 2.31)
0.98 (0.82 to 1.17)
0.85 (0.68 to 1.07)
1.05 (0.87 to 1.25)
0.98 (0.91 to 1.05)
098 (0.90 to 1.06)
6.45
12.19
37.14
1.21
16.70
10.92
15.40
100.00
0.5 1 2
Trial
Vitamin E
reduces
risk of
stroke
Vitamin E
increases
risk of
stroke
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%) (fixed
effects)
83/5660
209/4761
509/14 238
22/2231
241/19 937
137/4083
237/7315
1438/58 225
Vitamin E
group
95/5664
180/4780
548/14 281
18/2264
246/19 939
151/4088
227/7326
1475/58 342
Placebo
group
No of events
Fig 2 | Relative risks of the effect of vitamin E on total stroke for individual trials and for the
pooled population
  HOPE 2000
14
  ATBC 200012
  WHS 200511
  WACS 20079
  PHS II 2008
13
Pooled results
  Fixed effects model
  Random effects model
1.31 (0.64 to 2.70)
1.22 (0.92 to 1.61)
0.92 (0.61 to 1.38)
1.50 (0.68 to 3.34)
1.70 (1.02 to 2.84)
1.22 (1.00 to 1.48)
1.22 (1.00 to 1.48)
7.10
48.61
26.25
5.47
12.57
100.00
0.5 1 2
Trial
Vitamin E
reduces
risk of
stroke
Vitamin E
increases
risk of
stroke
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%) (fixed
effects)
17/4761
108/14 238
44/19 937
15/4083
39/7315
223/50 334
Vitamin E
group
13/4780
89/14 281
48/19 939
10/4088
23/7326
183/50 414
Placebo
group
No of events
Fig 3 | Relative risks of the effect of vitamin E on haemorrhagic stroke for individual trials and
for the pooled population
  SPACE 200020
  ATBC 200012
  WHS 200511
  WACS 20079
  PHS II 200813
Pooled results
  Fixed effects model
  Random effects model
0.85 (0.27 to 2.70)
0.86 (0.75 to 0.99)
0.98 (0.81 to 1.20)
0.81 (0.64 to 1.02)
0.98 (0.80 to 1.19)
0.90 (0.82 to 0.99)
0.90 (0.82 to 0.99)
0.60
44.13
20.06
15.27
19.94
100.00
0.5 1 2
Trial
Vitamin E
reduces
risk of
stroke
Vitamin E
increases
risk of
stroke
Relative risk
(95% CI)
Relative risk
(95% CI)
Weight
(%) (fixed
effects)
5/97
373/14 238
194/19 937
121/4083
191/7315
884/45 670
Vitamin E
group
6/99
434/14 281
197/19 939
150/4088
196/7326
983/45 733
Placebo
group
No of events
Fig 4 | Relative risks of the effect of vitamin E on ischaemic stroke for individual trials and for
the pooled population
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were open label trials.
810However, for the analysis of
the effect of vitamin E on total stroke, there was no
evidence for heterogeneity (I
2=12.8%; P for heteroge-
neity=0.33), and meta-regression did not identify
blinding strategy as a significant source of heterogene-
ity (P=0.75). In addition, both trials did not provide
data for stroke subtypes, so they did not affect the dif-
ferential effect seen in our meta-analysis.
Third, intention to treat analysis is considered the
optimumanalysisapproachforrandomisedcontrolled
trials. One of the trials for the analysis on ischaemic
stroke did not specify the method of analysis.
27 How-
ever, excluding this trial did not change the result. We
also included trials irrespective of the participants’
morbidity status. However, there is no a priori reason
to believe that the effect of vitamin E should differ
betweenpeoplewhoarehealthy,whohaveriskfactors
for cardiovascular disease, or who have experienced
overt cardiovascular events. This is confirmed by our
dataasmeta-regressiondidnotindicatethatmorbidity
status of trial participants is a source of heterogeneity
(P=0.96 for total stroke, P=0.40 for ischaemic stroke,
and P=0.65 for haemorrhagic stroke).
Fourth, there is some indication that biological
effects may be even more complex than observed in
our meta-analysis. One trial among male smokers pre-
sented results for haemorrhagic stroke stratified
according to intracerebral and subarachnoid haemor-
rhage; these suggested that vitamin E particularly
increased the risk for fatal intracerebral haemorrhage
(relative risk 1.64 (95% confidence interval 0.93 to
2.90)) and fatal subarachnoid haemorrhage (relative
risk 2.81 (1.37 to 5.79)).
12 However, the other trials
did not report these subcategories, and we could not
further investigate this in our systematic review.
Fifth, participants of clinical trials are selected based
on certain inclusion and exclusion criteria, which
reflect the risk status of only a subgroup of the general
population. Hence, generalisability may be limited.
Lastly, vitamin E treatment differed by dosing regi-
men and source (see table). For example, natural
source vitamin E (RRR stereoisomer of α-tocopherol)
ismoreactivethansyntheticsourcevitaminE(racemic
mixture of all stereoisomers of α-tocopherol).
31 How-
ever, meta-regression did not indicate that vitamin E
dose is a source of heterogeneity among the studies.
Discussion of individual trials
Many large randomised controlled trials investigating
the effect of vitamin E on incident major cardio-
vascular events were performed during the past two
decades, but most did not find an overall significant
effect.
8-14 Likewise, two recent meta-analyses did not
find an effect on mortality from all causes, cardio-
vascular death, and stroke from all causes.
1516 Our
results of an overall null effect of vitamin E on total
stroke agree with these earlier reports. However, the
main outcomeeventsin these previoustrials—compo-
sites consisting of myocardial infarction, stroke, and
death due to cardiovascular disease—may be too
broad to capture the differential pathophysiology
underlying ischaemic and haemorrhagic events.
1819
Subgroup analyses from previous trials support this
concept by pointing towards a beneficial effect of vita-
min E on incident ischaemic stroke,
912while suggest-
ing a detrimental effect on incident haemorrhagic
stroke.
913The Alpha Tocopherol, Beta Carotene Can-
cer Prevention trial was the first, showing that in male
smokers 50 mg/day of vitamin E increased the risk of
haemorrhagic stroke.
12 This result was confirmed in
the Physicians’ Health Study II, which randomised
14641 male physicians from the United States to 400
IU vitamin E on alternate days or placebo.
13 Results
from the Women’s Health Study, which randomised
39876 apparently healthy women to 600 IU vitamin
E on alternate days or placebo, however, do not indi-
cateincreasedriskofhaemorrhagicstrokeinwomen.
11
Potential biological mechanisms
The potential pathophysiological mechanisms
explaining these results are undetermined. Evidence
suggeststhatα-tocopherolinhibitsplateletaggregation
andadhesioninvitro,butitisnotclearthattheseeffects
on platelet function are deleterious in normal healthy
individualsatanydose.
32SinceresultsoftheWomen’s
Health Study indicate reduced risk of venous throm-
boembolism among women randomised to vitamin
E,
33 an alternative hypothesis is that vitamin E inter-
feres with activation of vitamin K dependent clotting
factor and exerts an anticoagulant effect. Current
research agrees on the antioxidant properties of vita-
min E
1 and that lipid peroxidation plays a central role
in atherogenesis.
2 However, it is not known if the vita-
min E doses chosen in clinical trials are adequate to
prevent lipid peroxidation in humans and if vitamin
Eplaysanimportantroleinpreventinglipidperoxida-
tion at all.
34 In addition, novel research indicates that
vitamin E has important functions in the regulation of
membrane bound enzymes, cellular trafficking, gene
expression, and inflammatory responses.
35 The func-
tional implications of these mechanisms are not well
understood yet.
Itisalsounclearwhetherthepropensityforbleeding
isrestrictedtotheintracranialcavityorwhetheritmay
be a general feature in vitamin E treatment. Data on
adversebleedingfromtherandomisedcontrolledtrials
arescarce:onetrialreportedtwocasesoffatalbleeding
in the intervention arm (2/97 given vitamin E
v 0/99 given placebo),
27 and one reported non-fatal
bleedings (16/2231 given vitamin E v 14/2264 given
placebo).
8 Among three large trials recording any
bleeding,
91113the Women’s Health Study particularly
focused on bleeding at multiple sites, and found no
overall increased rate of bleeding but a small signifi-
cantly increased risk for epistaxis among patients trea-
ted with vitamin E (relative risk 1.06 (95% confidence
interval 1.01 to 1.11), P=0.02).
11
Implications for clinical practice
While our data show a significantly reduced risk for
ischaemic stroke and increased risk for haemorrhagic
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rhagic strokes and 2.1 fewer ischaemic strokes per
1000 treated persons). In addition, one has to keep in
mind that other preventive strategies have far stronger
effects on stroke.
36 For example, the 10% relative risk
reduction for ischaemic stroke by vitamin E is negligi-
ble compared to the substantial risk reduction
achieved by antihypertensive medication
3738 or lipid
lowering medication.
39 In addition, as living a healthy
lifestyle,includingabstinencefromsmoking,keepinga
low body mass index, moderate alcohol consumption,
regular exercise, and a healthy diet has been consis-
tently associated with substantially reduced risk of
ischaemic stroke,
4041 intake of vitamin E supplements
may not further add to the risk reduction. Because the
consequencesof haemorrhagic strokein termsof mor-
bidity and mortality are generally more severe than
those of ischaemic stroke
42 and high doses of vitamin
E supplements may increase all cause mortality,
17 a
widespreadandmedically uncontrolleduse ofvitamin
E should be cautioned.
Directions for future research
Further research is warranted to understand mechan-
isms of the observed diametric effects on stroke sub-
types, in particular if and how the vitamin E effect is
modified by additional risk factors for haemorrhagic
and ischaemic stroke. We further need to understand
whether subgroups of individuals exist for whom vita-
min Econfers a substantialincreasedriskor decreased
risk for specific stroke subtypes. This may facilitate
evaluation of an individual risk-benefit balance and
help guiding physicians in the future. In addition, vita-
min E supplementation may have a different effect on
stroke and other cardiovascular disease events in
developing countries where malnutrition may be
found. This may be important since stroke burden
and mortality is highest in low income countries.
43
Conclusion
In this meta-analysis of randomised trials, we found
that vitamin E increased the risk for haemorrhagic
strokeby22%andreducedtheriskofischaemicstroke
by 10%. Using total stroke as the outcome obscures
these harms and benefits. However, given the rela-
tively small reduction in risk of ischaemic stroke and
the generally more severe outcome of haemorrhagic
stroke, indiscriminate widespread use of vitamin E
should be cautioned against.
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